Alkermes (ALKS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Alkermes Revenue Highlights

Latest Revenue (Y)

$1.66B

Latest Revenue (Q)

$378.14M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Alkermes Revenue by Period

Alkermes Revenue by Year

Date	Revenue	Change
2023-12-31	$1.66B	49.61%
2022-12-31	$1.11B	-5.28%
2021-12-31	$1.17B	13.00%
2020-12-31	$1.04B	-11.29%
2019-12-31	$1.17B	7.01%
2018-12-31	$1.09B	21.13%
2017-12-31	$903.37M	21.15%
2016-12-31	$745.69M	18.68%
2015-12-31	$628.34M	1.54%
2014-12-31	$618.79M	7.51%
2013-03-31	$575.55M	47.59%
2012-03-31	$389.98M	108.95%
2011-03-31	$186.64M	4.69%
2010-03-31	$178.28M	-45.45%
2009-03-31	$326.84M	35.78%
2008-03-31	$240.72M	0.31%
2007-03-31	$239.97M	44.04%
2006-03-31	$166.60M	118.85%
2005-03-31	$76.13M	94.92%
2004-03-31	$39.05M	-17.37%
2003-03-31	$47.27M	-12.63%
2002-03-31	$54.10M	-3.44%
2001-03-31	$56.03M	144.45%
2000-03-31	$22.92M	-47.57%
1999-03-31	$43.72M	39.55%
1998-03-31	$31.33M	58.00%
1997-03-31	$19.83M	41.62%
1996-03-31	$14.00M	13.82%
1995-03-31	$12.30M	57.69%
1994-03-31	$7.80M	-17.89%
1993-03-31	$9.50M	-

Alkermes generated $1.66B in revenue during NA 2023, up 49.61% compared to the previous quarter, and up 152.01% compared to the same period a year ago.

Alkermes Revenue by Quarter

Date	Revenue	Change
2024-09-30	$378.14M	-5.26%
2024-06-30	$399.13M	13.92%
2024-03-31	$350.37M	-7.18%
2023-12-31	$377.48M	-0.91%
2023-09-30	$380.94M	-38.30%
2023-06-30	$617.40M	114.68%
2023-03-31	$287.60M	-5.61%
2022-12-31	$304.67M	20.73%
2022-09-30	$252.36M	-8.64%
2022-06-30	$276.22M	-0.84%
2022-03-31	$278.55M	-14.15%
2021-12-31	$324.46M	10.31%
2021-09-30	$294.14M	-3.15%
2021-06-30	$303.72M	20.80%
2021-03-31	$251.43M	-10.20%
2020-12-31	$280.00M	5.65%
2020-09-30	$265.01M	7.06%
2020-06-30	$247.53M	0.53%
2020-03-31	$246.22M	-40.34%
2019-12-31	$412.73M	61.70%
2019-09-30	$255.24M	-8.80%
2019-06-30	$279.87M	25.45%
2019-03-31	$223.10M	-29.34%
2018-12-31	$315.76M	26.95%
2018-09-30	$248.72M	-18.36%
2018-06-30	$304.64M	35.31%
2018-03-31	$225.15M	-18.24%
2017-12-31	$275.37M	26.67%
2017-09-30	$217.38M	-0.67%
2017-06-30	$218.84M	14.11%
2017-03-31	$191.78M	-10.18%
2016-12-31	$213.51M	18.46%
2016-09-30	$180.24M	-7.65%
2016-06-30	$195.16M	24.49%
2016-03-31	$156.77M	-3.88%
2015-12-31	$163.10M	6.84%
2015-09-30	$152.65M	0.85%
2015-06-30	$151.37M	-6.11%
2015-03-31	$161.21M	-7.96%
2014-12-31	$175.16M	9.48%
2014-09-30	$159.99M	4.28%
2014-06-30	$153.42M	17.83%
2014-03-31	$130.21M	-6.86%
2013-09-30	$139.80M	0.84%
2013-06-30	$138.63M	-15.17%
2013-03-31	$163.42M	20.24%
2012-12-31	$135.91M	9.62%
2012-09-30	$123.98M	-18.56%
2012-06-30	$152.24M	16.68%
2012-03-31	$130.47M	3.84%
2011-12-31	$125.64M	74.56%
2011-09-30	$71.98M	16.31%
2011-06-30	$61.88M	21.01%
2011-03-31	$51.14M	16.29%
2010-12-31	$43.98M	-10.71%
2010-09-30	$49.25M	16.48%
2010-06-30	$42.28M	9.89%
2010-03-31	$38.48M	-12.86%
2009-12-31	$44.15M	-8.32%
2009-09-30	$48.16M	1.39%
2009-06-30	$47.50M	8.25%
2009-03-31	$43.88M	-71.81%
2008-12-31	$155.66M	229.02%
2008-09-30	$47.31M	-40.86%
2008-06-30	$79.99M	28.18%
2008-03-31	$62.41M	-

Alkermes generated $378.14M in revenue during Q3 2024, up -5.26% compared to the previous quarter, and up 61.25% compared to the same period a year ago.

Alkermes Revenue Breakdown

Alkermes Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Vivitrol	$400.42M	$379.48M	$343.85M	$335.37M	-
Aristada And Aristada Initio	$327.69M	$302.05M	$275.36M	-	-
L Y B A L V I	$191.89M	$96.02M	$8.21M	-	-
Product	$920.00M	$777.55M	$627.42M	$524.50M	-
Research And Development	-	-	-	$1.95M	-
Manufactured Product And Royalty	-	-	-	$22.50M	-
License	-	-	-	$1.05M	-
Aristada Or Aristada Initio	-	-	-	-	$189.13M

Alkermes's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), Vivitrol (21.76%), Aristada And Aristada Initio (17.81%), and L Y B A L V I (10.43%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
L Y B A L V I	$74.70M	$71.35M	$57.01M	$153.90M	$37.99M	$34.91M	$20.06M	$13.93M	-	-	-	-	-	-	-	-	-	-	-	-
Vivitrol	$113.65M	$111.87M	$97.66M	$303.76M	$96.66M	$101.98M	$96.11M	$84.85M	$92.04M	$88.86M	$88.42M	$74.53M	$71.65M	$78.77M	$85.16M	-	-	-	-	-
Product	$273.00M	$269.27M	$233.54M	$705.27M	$214.73M	$216.12M	$190.79M	$171.27M	$178.92M	$157.74M	$160.81M	$129.96M	$148.96M	$142.66M	$130.41M	$129.73M	$138.77M	-	-	-
Aristada And Aristada Initio	$84.65M	$86.05M	$78.87M	$247.61M	$80.08M	$79.23M	$74.62M	$72.48M	$78.66M	$68.87M	$72.39M	$55.43M	-	-	-	-	-	-	-	-
Manufacturing Revenue	-	-	-	-	$40.62M	$31.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.05M	$144.75M	-	-	-
Research And Development	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$141.00K	$953.00K	$11.08M	-	-	-
Aristada Or Aristada Initio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$58.77M	$50.96M	-	-
License And Service	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$5.00M	-
Aristada	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$53.61M

Alkermes's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (50.00%), Vivitrol (20.82%), Aristada And Aristada Initio (15.50%), and L Y B A L V I (13.68%).

Alkermes Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Foreign Country Excluding Specified Country	$170.29M	$177.97M	$187.34M	$196.53M	$200.82M
UNITED STATES	$1.49B	$931.99M	$984.24M	$839.00M	$966.93M
IRELAND	$1.18M	$1.83M	$2.17M	$3.23M	$3.19M

Alkermes's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (89.69%), Foreign Country Excluding Specified Country (10.24%), and IRELAND (0.07%).

Quarterly Revenue by Country

Country	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
Aristada And Aristada Initio	$80.08M	$79.23M	$74.62M	$72.48M	$78.66M	$68.87M	$72.39M	$55.43M	-	-	-	-	-	-	-	-	-	-	-	-
Vivitrol	$96.66M	$101.98M	$96.11M	$84.85M	$92.04M	$88.86M	$88.42M	$74.53M	$71.65M	$78.77M	$85.16M	$83.83M	$79.89M	$76.20M	-	-	-	-	-	-
Product	$214.73M	$216.12M	$190.79M	$171.27M	$178.92M	$157.74M	$160.81M	$129.96M	$148.96M	$142.66M	$130.41M	$129.73M	$138.77M	$136.63M	$99.48M	-	-	-	-	-
L Y B A L V I	$37.99M	$34.91M	$20.06M	$13.93M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	-	-	-	-	$1.05M	$144.75M	$1.00M	$48.30M	-	-	-	-	-	-	-
Research And Development	-	-	-	-	-	-	-	-	$141.00K	$953.00K	$11.08M	$14.34M	$14.71M	$1.50M	-	-	-	-	-	-
Aristada Or Aristada Initio	-	-	-	-	-	-	-	-	-	-	$58.77M	$50.96M	-	-	-	-	-	-	-	-
License And Service	-	-	-	-	-	-	-	-	-	-	-	-	$5.00M	-	-	-	-	-	-	-
Aristada	-	-	-	-	-	-	-	-	-	-	-	-	-	$53.61M	$48.82M	$36.14M	$33.60M	-	-	-
Manufactured Product And Royalty	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$127.90M	$108.92M	$114.60M	-	-	-
Clinical Supply	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$200.00K	-	-	-
R I S P E R D A L C O N S T A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.32M	-	-
Other Products And Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.89M	-	-
Invega Sustenna Or Xeplion And Invega Trinza	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$65.62M	-	-
B Y D U R E O N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$11.94M	-	-
A M P Y R A Or F A M P Y R A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.45M	-	-

Alkermes's latest quarterly revenue breakdown by geography, as of Mar 23: Product (50.00%), Vivitrol (22.51%), Aristada And Aristada Initio (18.65%), and L Y B A L V I (8.85%).

Alkermes Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RDY	Dr. Reddy's Laboratories	$279.16B	-
NBIX	Neurocrine Biosciences	$1.89B	$622.10M
ALKS	Alkermes	$1.66B	$378.14M
PBH	Prestige Consumer Healthcare	$1.13B	$283.55M
PAHC	Phibro Animal Health	$977.89M	$273.16M
PCRX	Pacira BioSciences	$674.98M	$168.57M
AMPH	Amphastar Pharmaceuticals	$593.24M	$188.82M
COLL	Collegium Pharmaceutical	$566.77M	$159.30M
ANIP	ANI Pharmaceuticals	$486.82M	$148.33M
ITCI	Intra-Cellular Therapies	$462.18M	$175.38M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
EGRX	Eagle Pharmaceuticals	$316.61M	$64.65M
DVAX	Dynavax	$232.28M	$79.34M
EOLS	Evolus	$199.72M	$60.16M
DCPH	Deciphera Pharmaceuticals	$163.36M	$45.00M

ALKS Revenue FAQ

What is Alkermes’s yearly revenue?

Alkermes's yearly revenue for 2023 was $1.66B, representing an increase of 49.61% compared to 2022. The company's yearly revenue for 2022 was $1.11B, representing a decrease of -5.28% compared to 2021. ALKS's yearly revenue for 2021 was $1.17B, representing an increase of 13.00% compared to 2020.

What is Alkermes’s quarterly revenue?

Alkermes's quarterly revenue for Q3 2024 was $378.14M, a -5.26% decrease from the previous quarter (Q2 2024), and a -0.73% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $399.13M, a 13.92% increase from the previous quarter (Q1 2024), and a -35.35% decrease year-over-year (Q2 2023). ALKS's quarterly revenue for Q1 2024 was $350.37M, a -7.18% decrease from the previous quarter (Q4 2023), and a 21.83% increase year-over-year (Q1 2023).

What is Alkermes’s revenue growth rate?

Alkermes's revenue growth rate for the last 3 years (2021-2023) was 41.72%, and for the last 5 years (2019-2023) was 42.06%.

What are Alkermes’s revenue streams?

Alkermes's revenue streams in c 23 are Vivitrol, Aristada And Aristada Initio, L Y B A L V I, and Product. Vivitrol generated $400.42M in revenue, accounting 21.76% of the company's total revenue, up 5.52% year-over-year. Aristada And Aristada Initio generated $327.69M in revenue, accounting 17.81% of the company's total revenue, up 8.49% year-over-year. L Y B A L V I generated $191.89M in revenue, accounting 10.43% of the company's total revenue, up 99.84% year-over-year. Product generated $920M in revenue, accounting 50.00% of the company's total revenue, up 18.32% year-over-year.

What is Alkermes’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Alkermes was Product. This segment made a revenue of $920M, representing 50.00% of the company's total revenue.